Aging & Elder Health Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging & Elder Health Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
GenVec, Inc.
Phase 1 myoblast cell transplantation study data presented at cardiology meeting
April 10th, 2005
GenVec, Inc. (GNVC), announced that 3 year follow-up data from a phase 1 study of its myoblast cell transplantation therapy for congestive heart failure were presented at the 2005 American College of Cardiology's Annual Scientific Session in Orlando, Florida. The purpose of this multicenter study was to demonstrate the safety and feasibility of using autologous myoblast transplantation to repair damaged heart tissue in patients who have suffered a heart attack. In the study, myoblasts were harvested from the leg muscles of 30 patients and then cultured using GenVec's proprietary technique. Twenty-four patients received escalating doses of each...
Source: Aging & Elder Health Week (2005-04-10)
|
